Download PDF

1. Company Snapshot

1.a. Company Description

Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Europe, North America, the Asia-Pacific, and internationally.It offers personalized kinematic models and 3D planning tools for use in hip, knee, shoulder, sports medicine, and spine procedures.The company was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.

Show Full description

1.b. Last Insights on MOVE

Medacta Group SA's recent performance was driven by a robust financial performance, with significant revenue and profit increases. The company's full-year 2024 earnings call highlighted record growth, despite navigating market challenges and strategic acquisitions. Notably, Medacta's robust financial performance was underscored by a 14.1% year-over-year increase in revenue, with the company's strategic acquisitions contributing to this growth. Additionally, the company's ability to navigate market challenges and adapt to changing conditions has been a key factor in its success.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

There May Be Underlying Issues With The Quality Of Medacta Group's (VTX:MOVE) Earnings

Sep -14

Source:

Card image cap

Medacta Group First Half 2025 Earnings: EPS: €3.01 (vs €1.91 in 1H 2024)

Sep -11

Source:

Card image cap

What Is Medacta Group SA's (VTX:MOVE) Share Price Doing?

Sep -01

Source:

Card image cap

The recent 3.5% gain must have brightened CEO Francesco Siccardi's week, Medacta Group SA's (VTX:MOVE) most bullish insider

Aug -13

Source:

Card image cap

Is Medacta Group SA's (VTX:MOVE) Recent Stock Performance Tethered To Its Strong Fundamentals?

Jul -04

Source:

Card image cap

Medacta Group SA (XSWX:MOVE) Full Year 2024 Earnings Call Highlights: Record Growth and ...

Mar -26

Source:

Card image cap

Investing in Medacta Group (VTX:MOVE) a year ago would have delivered you a 24% gain

Apr -02

Source:

Card image cap

Medacta Group Full Year 2023 Earnings: Misses Expectations

Mar -19

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.52%)

6. Segments

Hip

Expected Growth: 10%

Medacta Group SA's Hip segment growth is driven by increasing demand for orthopedic implants, an aging population, and a growing need for revision surgeries. Additionally, advancements in technology, such as robotic-assisted surgeries, and expanding market presence in emerging economies contribute to the 10% growth rate.

Knee

Expected Growth: 11%

Medacta Group SA's Knee segment growth of 11% is driven by increasing demand for minimally invasive surgeries, adoption of personalized medicine, and expansion into emerging markets. Additionally, the company's innovative products, such as the GMK Sphere, and strategic partnerships are contributing to market share gains.

Spine

Expected Growth: 12%

Medacta Group SA's Spine segment growth is driven by increasing demand for minimally invasive spine surgeries, adoption of innovative technologies such as robotic-assisted procedures, and expansion into emerging markets. Additionally, the company's focus on personalized medicine and customized implant solutions contributes to its 12% growth rate.

Shoulder

Expected Growth: 9%

Medacta Group SA's 9% growth is driven by increasing demand for orthopedic implants, expansion into emerging markets, and strategic partnerships. The company's innovative products, such as the AMIS hip system, and its focus on personalized medicine are also contributing to growth. Additionally, the rising prevalence of osteoarthritis and the increasing need for joint replacement surgeries are driving demand for Medacta's products.

Sportsmed

Expected Growth: 13%

Sportsmed's 13% growth is driven by increasing demand for orthopedic implants, particularly in the sports medicine segment, fueled by an aging population and rising sports-related injuries. Additionally, Medacta's innovative products, such as its proprietary MySpine MC platform, and strategic partnerships are contributing to the segment's growth.

Other

Expected Growth: 8%

Medacta Group SA's 8% growth is driven by increasing adoption of robotic-assisted surgeries, expansion into emerging markets, and strategic partnerships. Additionally, the company's focus on personalized medicine and innovative orthopedic implants contributes to its growth. Furthermore, the rising demand for minimally invasive surgeries and the increasing prevalence of orthopedic disorders also support the company's growth momentum.

7. Detailed Products

AMIS

Advanced Medacta Individualized Solutions, a personalized hip replacement system that allows for customized implant solutions

MySpine

A comprehensive range of spinal implants and instruments for various spinal procedures

MPower

A modular, porous, and customizable acetabular system for hip replacement

GMK Sphere

A modular, porous, and customizable knee replacement system

MyShoulder

A comprehensive range of shoulder implants and instruments for various shoulder procedures

Medacta Orthopaedic Surgery Navigation

A computer-assisted navigation system for orthopedic surgeries

8. Medacta Group SA's Porter Forces

Forces Ranking

Threat Of Substitutes

Medacta Group SA operates in the medical technology industry, which is characterized by a moderate threat of substitutes. While there are alternative treatments and products available, Medacta's focus on innovative and minimally invasive solutions reduces the threat of substitutes.

Bargaining Power Of Customers

Medacta Group SA's customers, primarily hospitals and medical professionals, have limited bargaining power due to the company's strong brand reputation and the specialized nature of its products.

Bargaining Power Of Suppliers

Medacta Group SA's suppliers, primarily manufacturers of medical devices and components, have a moderate level of bargaining power due to the company's dependence on a few key suppliers.

Threat Of New Entrants

The medical technology industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise, making it difficult for new entrants to compete with established players like Medacta Group SA.

Intensity Of Rivalry

The medical technology industry is highly competitive, with several established players competing for market share. Medacta Group SA faces intense rivalry from companies like Zimmer Biomet, Stryker, and Johnson & Johnson, which can lead to pricing pressure and increased marketing expenses.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 37.96%
Debt Cost 4.19%
Equity Weight 62.04%
Equity Cost 9.76%
WACC 7.65%
Leverage 61.20%

11. Quality Control: Medacta Group SA passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Medacta

A-Score: 4.8/10

Value: 0.9

Growth: 6.6

Quality: 6.8

Yield: 0.6

Momentum: 7.0

Volatility: 6.7

1-Year Total Return ->

View Full Report
Stock-Card
Getinge

A-Score: 4.3/10

Value: 3.4

Growth: 3.8

Quality: 5.2

Yield: 3.1

Momentum: 4.0

Volatility: 6.0

1-Year Total Return ->

View Full Report
Stock-Card
Demant

A-Score: 4.0/10

Value: 3.6

Growth: 6.8

Quality: 6.4

Yield: 0.0

Momentum: 2.0

Volatility: 5.3

1-Year Total Return ->

View Full Report
Stock-Card
LivaNova

A-Score: 3.8/10

Value: 6.2

Growth: 5.8

Quality: 4.0

Yield: 0.0

Momentum: 4.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Ambu

A-Score: 3.0/10

Value: 0.8

Growth: 5.9

Quality: 6.2

Yield: 0.0

Momentum: 2.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
GN Store Nord

A-Score: 2.8/10

Value: 5.5

Growth: 4.2

Quality: 4.1

Yield: 0.0

Momentum: 2.0

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

151.2$

Current Price

151.2$

Potential

-0.00%

Expected Cash-Flows